Pharmos — Investor Presentation (June 2006)
31 slides from Pharmos's investor presentation, Jun 6, 2006

Slide 1: Investor Presentation June 6, 2006
Investor Presentation June 6, 2006 PHARMOS

Slide 2: Safe Harbor Statement
Safe Harbor Statement The introductory remarks and the Company’s responses to questions will include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as “hope,” “may,” “believe,”

Slide 3: Additional Information about the Merger and Where to Find It
Additional Information about the Merger and Where to Find It In connection with its merger with Vela Pharmaceuticals Inc., Pharmos has filed a preliminary proxy statement and other relevant materials with the Securities and Exchange Commission (SEC) relating to a meeting of shareholders. Investors a

Slide 4: Pharmos Investment Highlights
Pharmos Investment Highlights Focus on CNS (including brain-gut), pain, inflammation Significant market opportunity for leading IBS therapeutic Proprietary/novel cannabinoid library Strategic objective: Acquire later-stage assets Vela acquisition announced March 2006 Establishes leadership positions

Slide 5: The Vela Acquisition Summary
The Vela Acquisition Summary Fulfills strategic objective / excellent fit Expands pipeline – later stage clinical drugs Complements focus on CNS/inflammation Dextofisopam – successful Phase 2a in IBS Two additional later-stage assets Tianeptine – strong follow-on for IBS VPI-013 – Phase 2 asset for

Slide 6: Deal Highlights
Deal Highlights Stock and cash transaction Initial payout: 11.5 million shares $5 million cash Performance milestones totaling 8 million shares 4 million on successful completion of Phase 2b 4 million on submission of NDA New board members Tony Evnin, Ph.D., of Venrock Associates Chuck Newhall III o

Slide 7: The New Pharmos Pipeline
The New Pharmos Pipeline Preclinical Phase 1 Phase 2 Phase 3 Dextofisopam IBS Tianeptine VPI-013 BF-036 Autoimmune Neuropathic Pain Topical NSAID’s * Nano Diclofenac for OA Nano Ketorolac for OA Cannabinor Nociceptive Pain Neuropathic Pain * Nano-Tech emulsion delivery IBS Female Sexual Dysfunction

Slide 8: IBS Overview
IBS Overview PHARMOS

Slide 9: IBS: A Prevalent Disease
IBS: A Prevalent Disease 9.1 2.7 2.2 2.2 1.8 1.2 0.5 3.7 GERD IBS Peptic Ulcer Diverticular Disease Chronic Diarrhea Colorectal Cancer Crohn's Disease Ulcerative Colitis Source : Sandler et al. The burden of selected digestive diseases in the United States. Gastroenterology 122:1500-1511, 2002 (data

Slide 10: IBS: A Significant Underserved Market
IBS: A Significant Underserved Market Diarrhea- Predominant 36% Constipation- Predominant 31% Alternating Diarrhea and Constipation 33% 5-HT 3 Antagonist Lotronex ® (GSK) Indication: women / severe d-IBS Boxed warning: serious GI AEs (ischemic colitis) High constipation rate (29%) Registry 5-HT 4 Ag

Slide 11: IBS: A Significant Underserved Market
IBS: A Significant Underserved Market Diarrhea- Predominant 36% Constipation- Predominant 31% Alternating Diarrhea and Constipation 33% 5-HT 3 Antagonist Lotronex ® (GSK) • Sales: $10 - 12 million* 5-HT 4 Agonist Zelnorm ® (Novartis) • Sales: $370 - 380 million* * Projected 2006 Dextofisopam

Slide 12: Dextofisopam
Dextofisopam PHARMOS

Slide 13: Dextofisopam: Leading Asset in Development for IBS
Dextofisopam: Leading Asset in Development for IBS Novel mechanism – different from other IBS drugs Older drugs (antispasmodics, antidiarrheals) Peripherally-acting anticholinergics or opiates Questionable efficacy, side effect issues Newer drugs (Lotronex ® , Zelnorm ® ) Peripherally-acting seroton

Slide 14: No Safe, Effective Drugs on Near Horizon: Other Later-stage Assets for IBS
No Safe, Effective Drugs on Near Horizon Other Later-stage Assets in Development for IBS Phase 1 c-IBS completed (Oct 2005) Phase 2 Microbia MD-1100 Guanylate cyclase C agonist 5HT 3 partial agonist Phase 2 in c-IBS (Sep 2005) Phase 2 Dynogen DPP-773 Approved for travelers’ diarrhea Some efficacy in

Slide 15: Dextofisopam: Proposed MOA Well Suited for IBS
Dextofisopam: Proposed MOA Well Suited for IBS Regulates autonomic tone at the level of the hypothalamus via atypical 2,3-BZ receptors 2,3-BZ receptors Classical benzo X Anti-inflammatory

Slide 16: Dextofisopam: Proposed MOA Well Suited for IBS
Dextofisopam: Proposed MOA Well Suited for IBS Regulates autonomic tone at the level of the hypothalamus via atypical 2,3-BZ receptors 2,3-BZ receptors Classical benzo X Anti-inflammatory

Slide 17: Dextofisopam: Phase 2a Study Design
Dextofisopam: Phase 2a Study Design Double-blind, US study (33 sites) 141 men and women with diarrhea-predominant or alternating IBS 200 mg BID dextofisopam or placebo for 12 weeks Primary endpoint * : “adequate relief” Weekly… • Patient friendly, global measure • FDA accepted measure Secondary endp

Slide 18: Dextofisopam: Phase 2a Study Results
Dextofisopam: Phase 2a Study Design Positive effect on primary efficacy endpoint 32% advantage vs. placebo Statistically significant (p = 0.033) Positive effect on key secondary efficacy endpoints Dextofisopam decreased stool frequency and improved (hardened) stool consistency in patients with d-IBS

Slide 19: Dextofisopam: A Potential First-line IBS Treatment
Dextofisopam: A Potential First-line IBS Treatment Novel dual mechanism – not serotonergic Excellent patent position COM through 2019, many additional patents filed Strong Phase 2a data Successful End of Phase 2a FDA meeting Phase 2b dose-ranging trial planned

Slide 20: Additional Assets
Additional Assets PHARMOS

Slide 21: Additional Vela Assets
Additional Vela Assets Tianeptine Follow-on to dextofisopam Preclinicals predict efficacy in IBS Potential to enter Phase 2 rapidly VPI-013 * Originally in development for depression Phase 2 trial missed depression endpoints Significantly improved sexual function Potential to develop for sexual dysf

Slide 22: Cannabinor Overview
Cannabinor Overview Cannabinor: the first CB2 molecule to clinic Active - pain animal models Nociceptive, neuropathic & visceral Activity opioids & NSAIDs Active - autoimmune animal models RA, MS

Slide 23: Cannabinor Clinical Trials
Cannabinor Clinical Trials Phase 1 trial completed (Dec 2005) IV formulation 48 healthy volunteers Linear pharmacokinetics Well tolerated Phase 2 pain trials in 2006 Nociceptive (Third molar extraction / 2Q2006) Neuropathic (4Q 2006) Optimizing oral formulation

Slide 24: Potential CB2 Leadership
Potential CB2 Leadership NP, Cancer Inflammatory Visceral Pain < 50 Peripherally Restricted THC Asthma Allergy < 10 > 100 CB2 Antagonist Obesity < 10 > 0.002 CB1 Antagonist NP RA Spasticity Bowel/Bladder < 50 > 50 2 nd Generation (036) Post Op. Cancer Pain < 100 > 10 Cannabinor Potential Indication(

Slide 25: Company Highlights
Company Highlights PHARMOS

Slide 26: Pharmos Trading/Financial Highlights
Pharmos Trading/Financial Highlights NASDAQ: PARS 3 mo. avg. daily volume: 93,100 Market capitalization: $46.1 million Recent price: $2.42 (6/2/06) 52-week high/low: $1.94 - $2.93 Financial (Pre-acquisition): 19.1 million shares outstanding $41.6 million cash/short-term investments ($2.24 per share,

Slide 27: Post-Vela Financial Highlights
Post-Vela Financial Highlights 30.5 million shares outstanding Performance milestone payments: 8 million shares 4 million shares: Successful completion Phase 2b 4 million shares: NDA submission < $40 million cash ($5 million to Vela shareholders) 2006 operational burn rate * = $19 - $20 million *Ass

Slide 28: The Business Strategy
The Business Strategy Create progressive specialty pharma company Focus: selective CNS, pain,inflammation Implement actionable plan Aggressive business development initiatives Optimize pipeline Align resources Metrics and monitoring Expedite building upon new foundation Infuse talent Expand product

Slide 29: Pharmos Investment Highlights
Pharmos Investment Highlights Focus on CNS (including brain-gut), pain, inflammation Significant market opportunity for leading IBS therapeutic Proprietary/novel cannabinoid library Strategic objective: Acquire later-stage assets Vela acquisition announced March 2006 Establishes leadership positions

Slide 30: Major Near-Term Milestones
Major Near-Term Milestones* 2006 Q2 Filed proxy for Vela acquisition Begin cannabinor Phase 2a nociceptive pain (third molar) trial Finalize dextofisopam Phase 2b IBS protocol Q3 Unblind data from cannabinor Phase 2a nociceptive pain trial Hold special shareholder meeting; close acquisition of Vela

Slide 31: PHARMOS
PHARMOS
Source: SEC EDGAR · 8-K filed Jun 6, 2006
